AI English summary of an SEC filing — figures as filed
Medtronic MDTThe company reported worldwide revenue of $8.961 billion for fiscal 2026 Q2, which ended October 24, 2025. It said revenue rose 6.6% as reported and 5.5% on an organic basis.
Key points
AI summaryThe company reported worldwide revenue of $8.961 billion for fiscal 2026 Q2, which ended October 24, 2025. It said revenue rose 6.6% as reported and 5.5% on an organic basis.
The company said GAAP net income attributable to Medtronic for Q2 was $1.374 billion and GAAP diluted EPS was $1.07, both up 8%. On a non-GAAP basis, net income was $1.746 billion and diluted EPS was $1.36, also up 8%.
The company raised its fiscal 2026 organic revenue growth outlook to about 5.5% from about 5.0%. It also raised its non-GAAP diluted EPS guidance to $5.62 to $5.66 from $5.60 to $5.66. The EPS outlook includes a potential tariff impact of about $185 million, unchanged from the prior outlook.
Medtronic said Cardiac Ablation Solutions revenue rose 71% in Q2, including 128% growth in the U.S., and it attributed the growth to the strength of its pulsed field ablation (PFA) portfolio. Cardiovascular segment revenue for the same quarter was $3.436 billion, up 10.8% as reported.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q2 Revenue $8.961 billion
The company reported worldwide revenue of $8.961 billion for fiscal 2026 Q2, which ended October 24, 2025. It said revenue rose 6.6% as reported and 5.5% on an organic basis.
Source · Based on the filing body and exhibits
Q2 Net Income and Diluted EPS
The company said GAAP net income attributable to Medtronic for Q2 was $1.374 billion and GAAP diluted EPS was $1.07, both up 8%. On a non-GAAP basis, net income was $1.746 billion and diluted EPS was $1.36, also up 8%.
Source · Based on the filing body and exhibits
Annual Outlook Raised
The company raised its fiscal 2026 organic revenue growth outlook to about 5.5% from about 5.0%. It also raised its non-GAAP diluted EPS guidance to $5.62 to $5.66 from $5.60 to $5.66. The EPS outlook includes a potential tariff impact of about $185 million, unchanged from the prior outlook.
Source · Based on the filing body and exhibits
Cardiac Ablation Solutions Revenue Up 71%
Medtronic said Cardiac Ablation Solutions revenue rose 71% in Q2, including 128% growth in the U.S., and it attributed the growth to the strength of its pulsed field ablation (PFA) portfolio. Cardiovascular segment revenue for the same quarter was $3.436 billion, up 10.8% as reported.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
You can verify the report’s figures and statements in the original filing on SEC EDGAR.